WEBULL
News
KOD
29.89
-3.83%
-1.19
Dynavax Technologies, Omeros, Agios Pharmaceuticals, Nike And Other Big Stocks Moving Higher On Wednesday
Benzinga · 3d ago
U.S. RESEARCH ROUNDUP-APi Group, Elf Beauty, Tesla
Reuters · 4d ago
KODIAK SCIENCES INC <KOD.O>: JEFFERIES RAISES TARGET PRICE TO $39 FROM $24
Reuters · 4d ago
Weekly Report: what happened at KOD last week (1215-1219)?
Weekly Report · 5d ago
Friday's After-Hours Gainers: Biotech And Genomics Stocks Show Strength
NASDAQ · 5d ago
Major Insider Move Signals Bold Confidence in Kodiak Sciences Stock
TipRanks · 12/20 02:05
Felix J. Baker, Director, Reports Acquisition of Kodiak Sciences Inc. Common Shares
Reuters · 12/19 21:07
*Kodiak Sciences Announces Closing of $184M Public Offering of Common Stock >KOD
Dow Jones · 12/19 02:08
Kodiak Sciences Raises Capital Through Completed Stock Offering
TipRanks · 12/18 21:50
Kodiak Sciences Announces Closing of $184 Million Public Offering of Common Stock including Full Exercise of Underwriters' Option to Purchase Additional Shares
Barchart · 12/18 19:26
BUZZ-U.S. STOCKS ON THE MOVE-Spotify, Robinhood Markets, Cannabis stocks
Reuters · 12/17 15:40
Toro, DBV Technologies, Udemy, ABM Industries And Other Big Stocks Moving Higher On Wednesday
Benzinga · 12/17 15:07
BUZZ-Kodiak Sciences surges after boosted $160 mln equity raise
Reuters · 12/17 14:45
BUZZ-U.S. STOCKS ON THE MOVE-Jabil, Texas Pacific Land, Texas Roadhouse
Reuters · 12/17 14:14
BUZZ-Kodiak Sciences dips after boosted $160 mln equity raise
Reuters · 12/17 13:39
Kodiak Sciences 6.956M share Spot Secondary priced at $23.00
TipRanks · 12/17 11:11
Kodiak Sciences prices upsized $160M stock offering at $23.00 per share
Seeking Alpha · 12/17 07:45
*Kodiak Sciences Prices Upsized Underwritten Public Offering of 6.96M Shares at $23.00 Per Share>KOD
Dow Jones · 12/17 04:02
*Kodiak Sciences: Gross Proceeds Expected to Be Approximately $160M >KOD
Dow Jones · 12/17 04:02
*Kodiak Sciences: Offering Expected to Close on or About Dec. 18 >KOD
Dow Jones · 12/17 04:02
More
Webull provides a variety of real-time KOD stock news. You can receive the latest news about Kodiak Sciences Inc. through multiple platforms. This information may help you make smarter investment decisions.
About KOD
Kodiak Sciences Inc. is a biopharmaceutical company. The Company has developed a new technology platform, the Antibody Biopolymer Conjugate (ABC) Platform, for retinal medicines. Its ABC Platform uses molecular engineering to merge the fields of protein-based and chemistry-based therapies. Its lead investigational medicine, tarcocimab tedromer, is a novel anti-vascular endothelial growth factor (anti-VEGF) antibody biopolymer conjugate under development for the treatment of high prevalence retinal vascular diseases, including diabetic retinopathy and wet age-related macular degeneration. Its second investigational medicine, KSI-501, is a bispecific antibody biopolymer conjugate designed to inhibit interleukin-6 (IL-6)-mediated inflammation and VEGF. It is also developing a third investigational medicine, KSI-101, an unconjugated bispecific protein targeting IL-6 and VEGF.